Business
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren’s disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presentation on October 26th at 10:30 am CDT BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics
About this update from Monte Rosa Therapeutics, Inc.
[{"type":"image","alt":"Monte Rosa Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Monte Rosa Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OzxkCVdlx.rHq4uLVBRKVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651","width":300,"height":82}},"lazy":false},{"type":"text","content":"MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model ","length":191,"tagName":"p"},{"type":"text","content":"Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren’s disease, systemic lupus erythematosus, and rheumatoid arthritis","length":190,"tagName":"p"},{"type":"text","content":"Poster presentation on October 26th at 10:30 am CDT","length":51,"tagName":"p"},{"type":"text","content":"BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of MRT-6160, a rationally designed molecular glue degrader (MGD) that selectively degrades VAV1, to treat multiple autoimmune and inflammatory diseases, at ACR Convergence 2025, held October 24-29 in Chicago, IL.","length":483,"tagName":"p"},{"type":"text","content":"“In a preclinical autoimmune disease model characterized by chronic inflammation, autoantibody production, and multi-organ involvement, administration of MRT-6160 resulted in broad activity across an array of disease markers, including attenuated autoantibody levels and reduced skin and kidney pathology,” said Sharon Townson, Ph.D., Chief Scientific Officer of Monte Rosa Therapeutics. “We believe these findings reinforce the breadth of MRT-6160's potential across multiple immune-mediated diseases, including systemic lupus erythematosus, Sjögren’s disease, rheumatoid arthritis, and others. These data also further highlight the potential capacity of MGDs to potently d...